Vertex Pharmaceuticals has discontinued its collaborative cystic fibrosis (CF) program with Moderna, citing concerns related to lung inflammation. The decision marks a significant shift for both companies, which had aimed to develop a new treatment option for CF patients not currently served by existing therapies. The halted program was designed to address the needs of…
